Most of the vitamins you know as a “hair and nails” supplement have never made headlines in an oncology lab. For decades, biotin (vitamin B7) has lived quietly on the shelves of drugstores, associated mostly with thicker hair and stronger nails. It is not a dramatic nutrient. It’s not associated with cancer prevention or cancer treatment. It’s just… there.
So when a team of scientists at the University of Lausanne published research earlier this year revealing that this same quiet vitamin plays a critical role in how some cancer cells survive, it caught the attention of researchers who have long been puzzled by one of oncology’s most stubborn problems: why cutting off a tumor’s main fuel so often fails to stop it from growing.
The discovery does not suggest that people need to worry about their biotin intake or that supplements should be avoided. What it does is far more useful: it gives researchers a clearer map of where cancer cells hide their spare keys and points toward which patients might respond best to therapies that have, so far, been hit-or-miss.
What Is Glutamine Addiction, and Why Is It Hard to Exploit?
Some cells become highly dependent on glutamine, an amino acid that plays a central role in cellular metabolism. This nutrient provides the essential building blocks for protein and DNA synthesis, and cells stop proliferating without it. In cancer, “glutamine addiction” is a well-known vulnerability of tumors, but many cancers manage to bypass it.
The term “addiction” is clinically apt. Glutamine not only supplies carbon and nitrogen for the synthesis of proteins and nucleotides but also supports energy generation and redox balance. Many tumor cells exhibit a phenomenon termed “glutamine addiction,” reflecting their heightened reliance on this amino acid for fueling their rapid proliferation. Scientists have been trying to exploit that reliance therapeutically for years.
Telaglenastat (CB-839) is a glutaminase inhibitor, a drug that targets dysregulation in glutamine metabolism in cancer cells and the tumor microenvironment. It has been tested in multiple clinical trials, often in combination with other agents. Despite being generally well tolerated, telaglenastat in combination with nivolumab was generally well tolerated, but it led to limited clinical activity across different study cohorts, according to a 2025 phase I/II study in ESMO Open. This pattern – promising preclinical rationale, disappointing clinical results – has been repeated across several glutamine-targeting strategies.
The 2026 University of Lausanne study offers a molecular explanation for why. Cancer cells can activate alternative metabolic pathways when glutamine is cut off, and the details of how they do it are now considerably clearer.
The Backup Plan Tumors Use to Survive
Cancer cells are notorious for their ability to adapt. Cut off one fuel source, and they often find another. Scientists at the University of Lausanne uncovered a cellular mechanism that reveals a hidden weakness in tumor cells when they are deprived of vitamin B7.
The research was spearheaded by Dr. Miriam Lisci, a postdoctoral researcher in Prof. Alexis Jourdain’s lab. The study, published in Molecular Cell and led by Lisci, reveals that cancer cells can switch to an alternative metabolic pathway driven by pyruvate, a carbon-rich molecule, to sustain proliferation in the absence of glutamine. Their experiments showed that this workaround depends on a mitochondrial enzyme known as pyruvate carboxylase. For this enzyme to operate, it must bind to vitamin B7 (or biotin). Without vitamin B7, the enzyme remains inactive, and cell growth comes to a halt.
Pyruvate carboxylase is not a new enzyme. The pathway itself is well-established in normal physiology, including gluconeogenesis (the process by which the liver generates glucose during fasting). What is new is the discovery that cancer cells exploit this same enzyme as a metabolic escape route when glutamine is scarce.
Researchers report that the vitamin biotin allows the bypassing of glutamine dependence by activating pyruvate carboxylase (PC). “If there is plenty of biotin and the enzyme is present, then the cancer cells will be able to survive even though this amino acid is absent,” Lisci explained. “But if biotin is not there, then this enzyme is not going to be active, and therefore they will be more sensitive to the lack of glutamine.” Without active pyruvate carboxylase, cells stall when deprived of glutamine.
How Vitamin B7 Functions as a “Metabolic License”
To understand why biotin’s role in this process matters, it helps to know what biotin normally does. The experiments reveal that this effect requires a mitochondrial enzyme called pyruvate carboxylase, which itself needs vitamin B7 (or biotin) to function. Without this vitamin, the enzyme is inactive and cells remain stalled. Biotin thus acts as a “metabolic license,” enabling pyruvate to fuel the cells’ energy cycle and compensate for the lack of glutamine.
Biotin also plays a broader role in normal metabolism. In this context, biotin functions as a “metabolic license,” making it possible for pyruvate to enter the cell’s energy-producing pathways and compensate for the absence of glutamine. According to Harvard’s T.H. Chan School of Public Health, biotin plays a vital role in assisting enzymes to break down fats, carbohydrates, and proteins in food, and it also helps regulate signals sent by cells and the activity of genes.
Most people get adequate biotin from food. This doesn’t mean people should start supplementing or avoiding biotin on their own. These pathways are highly specific to tumor biology and genetic mutations. It does show how nutrients like vitamin B7 play very precise roles at a cellular level, according to SciTechDaily’s coverage of this research. Severe biotin deficiency in healthy individuals eating a normal mixed diet has never been reported, according to the NIH Office of Dietary Supplements.
The findings were consistent across multiple cancer models. Although the researchers began with a specific cell line, they extended their analysis to a broad panel of cancer types. “We looked in 10 or 12 cancer types, and in all of them, this was applicable,” Jourdain said. Lisci added that the results held true across both mouse and human cancer cells, suggesting that the mechanism is widely conserved.
That breadth is notable, though it must be interpreted carefully. Because laboratory media let researchers dial vitamins and amino acids up or down, real tumors may respond differently. Next, animal studies and patient samples must show which tumors truly rely on the B7-pyruvate route.
The FBXW7 Gene: A New Layer of Vulnerability
The most immediately actionable part of the research may be what the team uncovered about FBXW7, a gene already associated with cancer risk across a range of tumor types.
FBXW7 is a critical tumor suppressor. Its job is to tag cancer-promoting proteins for disposal. When it stops working, those proteins accumulate and drive unchecked growth. FBXW7 influences the proteasome-facilitated breakdown of oncoproteins such as cyclin E, c-MYC, Mcl-1, mTOR, Jun, Notch, and AURKA, making FBXW7 gene loss an essential pathway in cancer progression.
Research published in Cancer Research established that the highest frequencies of FBXW7 mutations were observed in bile duct tumors (cholangiocarcinomas, 35%), blood cancers (T-cell acute lymphocytic leukemia, 31%), colon (9%), endometrium (9%), and stomach (6%). A 2025 systematic review indexed in PubMed found that mutations in FBXW7 occur in 6-10% of colorectal cancer cases, though the prognostic and predictive role of FBXW7 in colorectal cancer remains unclear, with inconsistent findings across studies.
What the new 2026 research adds is a metabolic dimension to FBXW7 mutations that was previously unknown. The study reports that biotin licenses proliferation of glutamine-deprived cells by promoting the activity of pyruvate carboxylase, and identifies an epigenetic mechanism whereby the tumor suppressor FBXW7 regulates glutamine addiction by promoting expression of pyruvate carboxylase.
Mutations in FBXW7 reduced levels of pyruvate carboxylase, impairing the cells’ ability to use pyruvate as an alternative fuel. As a result, these cells could no longer compensate for glutamine loss and became highly dependent on it. “This is because they actually lack this pathway that goes through biotin and pyruvate carboxylase,” Lisci said.
As Lisci explained, “When FBXW7 is mutated – a situation that is frequent in certain cancers – pyruvate carboxylase partially disappears, pyruvate can no longer be used efficiently, and cells become dependent on glutamine.” The researchers demonstrated that specific FBXW7 mutations found in patients can directly trigger this increased dependence on glutamine.
What This Could Mean for Future Therapies
The FBXW7-to-glutamine-addiction link transforms a mutation that has long been tracked as a general tumor marker into a potential biomarker for metabolic therapy selection.
Jourdain framed the finding within the broader logic of precision oncology. “That’s the principle of precision medicine,” he said. “Instead of treating the tumor as if it was any tumor, we check what are the mutations in those tumors. If they have the mutation in FBXW7, then we would predict that they would be more sensitive to therapies targeting glutamine metabolism.”
FBXW7 normally helps degrade MYC; when FBXW7 is mutated, MYC activity increases. The researchers showed that the metabolic rewiring observed in tumors occurs downstream of MYC signaling, further integrating oncogenic signaling with nutrient use. FBXW7 is one of the most commonly mutated tumor suppressors in human cancer, including colorectal cancer, T-cell leukemia, and cholangiocarcinoma. These cancers, with silenced pyruvate carboxylase, should be most vulnerable to glutamine-targeting therapies.
The glutaminase inhibitor telaglenastat, which targets glutamine metabolism enzymes, could theoretically be better matched to FBXW7-mutant tumors, though this hypothesis remains to be tested prospectively. These insights offer a compelling explanation for why some therapeutic strategies targeting glutamine metabolism have underperformed in clinical settings: cancer cells’ capacity to engage alternative metabolic pathways, such as the pyruvate carboxylase-dependent route enabled by biotin, confers resistance to glutamine deprivation.
In the longer term, “this research opens up new avenues for better understanding the metabolic vulnerabilities of cancers and for designing innovative therapeutic strategies that take into account the great metabolic flexibility of tumor cells, notably by targeting several metabolic pathways simultaneously,” concluded Jourdain, senior author of the study.
Study Design, Scope, and Limitations
Earlier studies highlighted metabolic pathways sustaining the proliferation of glutamine-deprived cells, but the field still lacked a global, systematic view of the nutrients and pathways involved in cell survival when glutamine is scarce. The team combined metabolic tracing with large-scale nutrient and genome-wide genetic screening to provide a unified model of the metabolites and molecular pathways involved in glutamine addiction.
The study was conducted in cell lines and extended across cancer types in laboratory conditions. These are preclinical findings. Real tumors may respond differently from how cells behave in a controlled lab environment. Human clinical trials testing biotin deprivation or combination metabolic blockade strategies are not yet established.
The collaboration involved the University of Lausanne’s metabolomics and proteomics platforms, as well as the team of Prof. Owen Skinner at Northeastern University in the United States. The paper was published in the journal Molecular Cell.
Read More: Foods That Can May Help Lower Cancer Risk
What This Means for You
This study is a significant piece of basic science. It is not a clinical trial, and it does not suggest that adjusting your biotin intake will affect cancer outcomes. What it does provide is a clearer picture of one of cancer biology’s most frustrating puzzles: why tumors resist metabolic targeting.
Several findings stand out. First, biotin availability acts as a gate-keeping factor for a cancer cell’s metabolic escape route. Without it, pyruvate carboxylase cannot function, and cells deprived of glutamine cannot pivot to pyruvate as an alternative fuel. Second, FBXW7 mutation status may function as a predictive biomarker for glutamine-targeting therapies. This has direct implications for trial design: enrolling patients with confirmed FBXW7 mutations in anti-glutamine studies could sharpen the signal that has been muddied in previous trials.
Third, the findings reinforce what is becoming a consensus position in metabolic oncology: cancer cells can activate alternative pathways to survive, using other nutrients when one source is cut off. Single-pathway targeting approaches may be insufficient given the metabolic flexibility these tumors display. Future research will need to determine whether targeting biotin-related pathways is safe for normal cells, which also rely on this vitamin – a caution the researchers themselves acknowledge.
For patients and the general public, the practical message is simple: do not begin altering biotin intake in response to this research. The mechanisms described operate at a cellular and genetic level specific to tumor biology, and no dietary or supplementation intervention has been studied or recommended in this context. For clinicians, the takeaway is awareness: patients with tumors harboring FBXW7 mutations may have a distinct metabolic profile that could, in future, inform treatment selection. The next step is translating these cellular insights into clinical tools – and that work is only just beginning.
Disclaimer: The author is not a licensed medical professional. The information provided is for general informational and educational purposes only and is based on research from publicly available, reputable sources. It is not intended to constitute, and should not be relied upon as, medical advice, diagnosis, or treatment. Always consult a licensed physician or other qualified healthcare provider regarding any medical condition, symptoms, or medications. Do not disregard, avoid, or delay seeking professional medical advice or treatment because of information contained herein.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: Deadly Brain Tumor Disappears After Experimental Cancer Treatment